

EuroEyes

EuroEyes International Eye Clinic Limited
德視佳國際眼科有限公司
(Stock Code: 1846.HK)

**EuroEyes named largest implanter of Zeiss AT LISA® tri IOLs in the world
for seven consecutive years**

EuroEyes is the only eye clinic to achieve this feat

Hong Kong, 6 July 2022 – EuroEyes International Eye Clinic Limited (“EuroEyes” or the “Company”, together with its subsidiaries, the “Group”, HKEX: 1846) a leading global vision correction service provider, announced today that it has been recognised as the largest implanter of Zeiss AT LISA® trifocal intraocular lens (IOL) worldwide for the 7th consecutive year. It is the only eye clinic in the world to achieve this milestone, having performed approximately 30,000 such presbyopia treatment surgeries between 2015 and 2021.



PHOTO CAPTION: Dr. Jørn S. Jørgensen, Founder, Chairman and CEO of EuroEyes (right), received the “ZEISS AT LISA® tri Certificate of Excellence” from Euan S. Thomson, PhD, President Ophthalmic Devices, Head of Digital Business, Carl Zeiss Meditec Inc.

Dr. Jørn S. Jørgensen, Founder, Chairman and CEO of EuroEyes, said: “We are pleased to be once again named the largest implanter of Zeiss AT LISA® tri IOLs worldwide, and I am exceptionally thrilled that we have retained this crown for seven years straight. This comes to show that not only are we the best in performing trifocal lens exchange surgeries, but also having a large number of patients who come to us for this type of treatment. This is a recognition of the trust that our patients have in us, and

we will continue to offer the most appropriate, most innovative vision correction solutions to them, whether they are in China, Germany, Denmark, or the UK.”

Since its founding in 1993, EuroEyes has over the years been using the latest technology in vision correction to help patients worldwide regain clear eyesight. Globally, it has served more than 600,000 patients, and has been a leader in performing trifocal lens exchange surgeries as a standalone treatment option for people with presbyopia.

In addition, EuroEye’s acquisition of London Vision Clinic in early 2022 further complements the company’s treatment options for presbyopia. Professor Dan Reinstein, founder of London Vision Clinic, pioneered the PRESBYOND® Laser Blended Vision, a minimally invasive laser treatment designed for patients from the age of 40 years old who have developed presbyopia. By implementing this technology into EuroEyes, the Group is able to treat a larger group of patients who are suffering from presbyopia at an early stage.

The latest recognition from Zeiss adds to the recent list of medical achievements at EuroEyes. In May 2022, the company received the “Leading EVO Visian ICL Implanter in Germany 2021” award from STAAR Surgical Company (“STAAR”) for the most Implantable Collamer® Lens (ICL) surgeries performed in Germany. In the same month, Dr. Jørn S. Jørgensen together with four other EuroEyes doctors received the “Germany’s Excellent Doctors 2022” award for refractive surgery from German news magazine *STERN* in the special issue “Gute Ärzte für mich” (Good Doctors for Me).

###

About EuroEyes International Eye Clinic Limited (1846.HK)

EuroEyes was established in 1993 and is one of the leading brands in the vision correction industry that combines German ophthalmology excellence and over 25 years of experience with individualised customer care. EuroEyes is one of the few eye clinic groups with a far-reaching geographical coverage, with operations in Germany, Denmark, the PRC and the United Kingdom. The Group’s vision correction services include (i) refractive laser surgery (which includes ReLEx smile and Femto LASIK); (ii) phakic lens (ICL) surgery; (iii) lens exchange surgery (which includes the monofocal and trifocal lens exchange surgery) and (iv) others (which include PRK/LASEK and ICRS implantation).

For more information, please contact:

EuroEyes International Eye Clinic Limited – ir@euroeyes.com

Hume Brophy Communications – Ashley So / Jane Hung / Connie Chan,
euroeyeshk@humbrophy.com